These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 10235532)

  • 21. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [18FDG-PET imaging of pancreatic adenocarcinoma].
    Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
    Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].
    Kysucan J; Lovecek M; Klos D; Tozzi I; Koranda P; Buriánková E; Neoral C; Havlík R
    Rozhl Chir; 2010 Aug; 89(7):433-40. PubMed ID: 20925260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases.
    Sánchez-Bueno F; García-Pérez R; Claver Valderas MA; de la Peña Moral J; Frutos Esteban L; Ortiz Ruiz E; Fuster Quiñonero M; Parrilla Paricio P
    Cir Esp; 2016 Nov; 94(9):511-517. PubMed ID: 27712835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
    Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of 18FDG PET for diagnosis of pancreatic tumors].
    Granov AM; Tiutin LA; Ryzhkova DV; Kostenikov NA; Fadeev NP; Savello VE; Pavlovskiĭ AV; Tlostanova MS; Efimenko AV; Stanzhevskiĭ AA
    Vestn Rentgenol Radiol; 2002; (2):18-22. PubMed ID: 12216484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms.
    Kalady MF; Clary BM; Clark LA; Gottfried M; Rohren EM; Coleman RE; Pappas TN; Tyler DS
    Ann Surg Oncol; 2002 Oct; 9(8):799-806. PubMed ID: 12374664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
    Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
    Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
    Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. THE USE OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY TO ASSESS CLINICAL OUTCOMES OF PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC CANCER.
    Durmus A; Yilmaz A; Malya F; Ozturk G; Bektasoglu H; Ertugrul G; Karyagar S; Karatepe O
    Georgian Med News; 2016 Apr; (253):26-9. PubMed ID: 27249430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.
    Einersen P; Epelboym I; Winner MD; Leung D; Chabot JA; Allendorf JD
    J Gastrointest Surg; 2014 Aug; 18(8):1441-4. PubMed ID: 24928186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
    Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
    BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.
    Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA
    Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
    Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
    Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.